University of Gent, Experimental Cancer Research Lab, Belgium
Some more on the speaker:
Since his PhD, he has been working on cancer-associated fibroblasts (CAFs) in colon cancer progression (De Wever et al., FASEBJ 2004, J Pathol 2003, J Cell Science 2004 over 1000 cumulative WOS citations). I He expanded his research into adipose tissue during his post-doc (Lapeire et al., Cancer Res 2014) and the secretory mechanisms of pro-metastatic signals (Hendrix et al., JNCI 2010, Cancer Res 2010). His current lab woks on tumor-environment interactions including design of model systems (De Jaeghere et al., Biomaterials 2018), response to therapy of CAFs (Tommelein et al., Cancer Res 2018), and exploitation of CAFs as therapy (De Vlieghere et al., Biomaterials 2015) and extracellular vesicles with the Hendrix lab (De Wever and Hendrix EMBOJ 2019).
Institut de Génétique Humaine, CNRS/Université de Montpellier
Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School
"Research in Dr Kruse's lab aims to elucidate the molecular basis of transmembrane signaling through the use of biochemistry, pharmacological studies, and structural biology. He is particularly interested in signaling pathways with connections to human health and disease, including G protein-coupled receptors and other transmembrane receptors. In the long term, he aims to leverage a detailed molecular understanding of these pathways to facilitate the development of new and better therapeutics."
Plus d'informations : https://kruse.hms.harvard.edu/home
Evergrande Center for Immunologic Diseases, Harvard Medical School
Contact : Antonio Maraver
This seminar dedicated to researchers at the IRCM will cover the following topics:
• CRISPR Experimental Design and Optimization (Knock-outs and Knock-ins)
• Synthego robust loss of function screens for confident target discovery
• Using CRISPR to uncover protein functions and pathway analysis
Join us for an interactive session about the latest CRISPR advances and applications. Discover the impact of CRISPR in cancer and genetic disease research.
Inscription obligatoire : https://www.synthego.com/events/ircm-virtual-crispr-seminar-05-20-2021?utm_campaign=Seminar&utm_medium=email&_hsmi=2&_hsenc=p2ANqtz-_sudq5Q7awlTD2lNg-tEEocSrQCLkfy39t8xve_RgWiIslJQj6y1Aa-O7uZKp9hvGvvXT94ctC5CdAPZRKzH8Sfyqs8A&utm_content=2&utm_source=hs_email
professeur d'immunologie moléculaire et directrice de l'immunologie translationnelle au Centre d'immunologie du cancer de la faculté de médecine de l'Université de Southampton
Professors Sally Ward and Raimund Ober have recently relocated their research group from the USA to Southampton. Their interdisciplinary research program is dedicated to the use of protein engineering to develop novel antibody-based therapeutics.
The identification in the Ward/Ober laboratory of the Fc receptor, FcRn, as a regulator of IgG levels and transport has resulted in significant interest in targeting FcRn in biopharma. Extensive analyses of FcRn behaviour, including subcellular trafficking studies, have led to collaborations with biopharma to develop several therapeutics that are based on modulating the interactions of IgG with FcRn. For example, one such therapeutic (Efgartigimod) that inhibits FcRn activity has been developed in collaboration with Argenx, and has recently been successfully used in phase 3 trials to treat antibody-mediated autoimmune diseases.
"The presentation will cover how a combination of antibody engineering, fluorescence microscopy and mouse disease models have been used to inform the design of therapeutics to modulate the dynamic behavior of antibodies for the treatment of autoimmunity. In particular, the targeting of the MHC Class I-related receptor, FcRn, that recycles and transports IgG to maintain IgG homeostasis will be discussed. The generation of engineered antibody-drug conjugates that are designed to deliver their cytotoxic payload more efficiently to tumor cells will also be presented"
PhD student – INSERM U1160, Intestinal Immunity in Inflammation and Cancer - Hôpital Saint Louis, Paris
« The 3IC team works on the intestinal immunity in inflammation and cancer, and more specifically on T cells. The intestine presents a particular immune system, constantly stimulated by exogenous antigens from food, commensal microbiota or pathogens. Specific regulations balance the immune response between tolerance of microbiota and food antigens, and protection against pathogens. This immune homeostasis is crucial and its perturbation are involved in several pathologies. Upon epithelial stress and continuous inflammation, an abnormal proinflammatory immune response can induce autoimmune reactions and chronic inflammation diseases, whereas an excessive tolerant phenotype established an immunosuppressive microenvironment favourable to cancer progression. In this tumor context, an antitumor T cell response is clearly engaged but the upregulation of immunosuppressive markers, like the immune checkpoints, allow the tumor immune escape. Immunotherapies targeting these markers, anti-PD-1 and anti-CTLA-4, were developed but presented a weak efficacy in colorectal cancer (CRC). New therapeutic strategies are necessary. In this project, we studied the antitumor T cell response involved in human CRC. Based on a prospective cohort, our objectives were to better characterize this response to find new potential target for immunotherapy and test their efficacy in our innovative autologous coculture model. We focused on several different pathways including CD39 and CD73. »
Contact IRCM : Laurent GROS
Nanolive, Genève, Suisse
Contact IRCM : Alexandre Djiane
Institute of Cancer Research, Medical University of Vienna, Austria
"Clinical evidence shows that, following initial response to treatment, drug-resistant cancer cells frequently evolve, and eventually most tumors become resistant to all available therapies. The most straightforward cause of therapy resistance is linked to cellular alterations that prevent drugs to act on their target. Upregulation of cell membrane efflux transporters of the ATP-binding cassette (ABC) superfamily leads to simultaneous resistance against structurally and functionally unrelated chemotherapeutic agents. In particular, P-glycoprotein (Pgp, MDR1), the product of ABCB1 gene, was shown to be expressed in several drug resistant malignancies. Based on the correlation of P-glycoprotein expression and function with unfavorable treatment response, it is universally accepted that pharmacological modulation of the MDR phenotype has the potential to significantly increase the efficacy of currently available anticancer therapies. Unfortunately, despite a few early successes, clinical trials conducted with Pgp inhibitors did not fulfill this expectation, failing to confirm clinical benefit. Failure of the trials led to a setback in research, and the shutdown of the pharmaceutical development of transporter inhibitors for the improvement of anticancer therapy. Yet the “transporter problem” has not vanished, as evidenced by new studies supporting the relevance and benefit of research on the role of ABC transporters in clinical drug resistance. Failure of the inhibitors has boosted research in other directions, exploring the possibility to evade efflux, or to exploit the paradoxical sensitivity associated with efflux-based drug resistance mechanisms. In this talk I will describe new approaches to combating multidrug-resistant cancer, including the development of drugs that engage, evade or exploit efflux by P-glycoprotein."
Contact IRCM : Charles Theillet
Le séminaire sera diffusé par Zoom. Un lien sera envoyé par mail quelques jours avant la date
This will be a Zoom webinar. A link will be sent by email in due time.
Institute of Cancer Research, Medical University Vienna
Contact IRCM: Charles Theillet
“Le séminaire sera diffusé en Webinaire Zoom. Le lien sera diffusé 2 jours avant la date prévue. Il sera transmis en salle de séminaire avec une audience limitée pour respecter la distanciation“